#China #Wuxi #WuXi Biologics #Sustainable Procurement #ISO 20400

WuXi Biologics Achieves ISO 20400 Certification

In a significant advancement for sustainable practices, WuXi Biologics (2269.HK) has proudly announced its receipt of the ISO 20400 certification, an internationally esteemed standard aimed at integrating sustainability into procurement activities. This milestone showcases the company's unwavering commitment to sustainable business practices that encompass transparency and accountability across its supply chain.

Commitment to Sustainability

Dr. Chris Chen, the CEO and Chairman of WuXi Biologics' ESG Committee, stated, "As an active participant in the Pharmaceutical Supply Chain Initiative (PSCI), we at WuXi Biologics strive to employ world-class management tactics that fortify our supply chain. Through these efforts, we aim to provide unparalleled quality solutions designed to meet the rising expectations of our global clients while also fostering a responsible advancement of the pharmaceutical industry."

Comprehensive Supplier Lifecycle Management

The achievement of ISO 20400 underscores the company's integration of sustainability within its supplier lifecycle management. WuXi Biologics has developed a rigorous framework that encompasses various stages, including supplier due diligence, risk management, and performance evaluation. This systematic approach not only ensures that suppliers maintain high standards of quality and compliance but also cultivates transparent and traceable supply chains that mitigate operational risks.

Engaging for Climate Action

In an age where climate change presents unprecedented challenges, WuXi Biologics has taken proactive measures to address these pressing issues. The organization has set measurable targets aligned with the Science Based Targets initiative (SBTi) and developed intricate roadmaps to realize these objectives. Importantly, the company collaborates with its suppliers to extend these sustainable practices throughout the value chain, facilitating positive impacts that benefit both the environment and business operations.

As a member of the United Nations Global Compact (UNGC), WuXi Biologics reinforces its advocacy for sustainable development, earning numerous accolades for its efforts, including:

• - MSCI AAA Rating
• - EcoVadis Platinum Medal
• - Inclusion in the Dow Jones Sustainability Indices
• - Designation on the CDP "A List" for Climate Change and Water Security
• - Recognition as a top-rated company in sustainability by Sustainalytics for five years consecutively
• - Membership in the FTSE4Good Index Series and Hang Seng ESG 50 Index

These achievements collectively reflect the company's steadfast dedication to not only meeting but exceeding the expectations of stakeholders and regulatory bodies alike.

About WuXi Biologics

WuXi Biologics has established itself as a leading global Contract Research, Development, and Manufacturing Organization (CRDMO). Its operations span globally with over 12,000 skilled personnel in regions such as China, the United States, Ireland, Germany, and Singapore. The organization focuses on providing integrated solutions that facilitate the discovery, development, and production of biologics—from initial concept to commercialization—thereby enhancing patient care worldwide.

With ongoing efforts to innovate in green technologies, WuXi Biologics is committed to expanding its environmentally friendly CRDMO solutions while maintaining excellence across Environment, Social, and Governance (ESG) metrics. The company emphasizes shared value creation by collaborating with all stakeholders to ensure the advancement of sustainable and responsible practices throughout the entire value chain.

For more information about WuXi Biologics and its initiatives, please visit www.wuxibiologics.com.